Following Phase I results, Merck will discontinue its development of V590 and V591, two COVID-19 vaccine candidates.
List view / Grid view
Filter the results
In this article, Alison Bourke, Scientific Director of the Center for Advanced Evidence Generation at IQVIA Health, explores how digitally-connected active and passive data sources are shaping the development of patient-centric treatments and care.
Japan has procurement deals with half of the companies leading the COVID-19 vaccine development race, according to GlobalData.
Researchers studying the microbiologic diagnosis of pneumonia have identified ways to optimise a pneumonia panel.
A new report has shown that the pharmaceutical industry in Scotland employs nine percent more people now than in 2018.
A clinical trial in hospitalised COVID-19 patients has demonstrated that baricitinib and remdesivir reduce time to recovery.
Synairgen's interferon beta therapy is being studied as a potential COVID-19 treatment in a Phase III trial as the first patient is dosed.
Two Phase III trials have shown that two doses of risankizumab met the primary endpoints in patients with Crohn's disease.
IL-6 receptor antagonists tocilizumab and sarilumab have a significant impact on COVID-19 patient mortality, a study has shown.
Bayer has signed a collaboration and services agreement with CureVac for the development of CVnCoV, a COVID-19 vaccine currently in late-stage trials.
Aimmune Therapeutics' PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
A study has shown that the use of oral contraceptives gave women a much lower risk of developing both ovarian and endometrial cancer.
The SILVAR study is designed to reaffirm the results of the SISCO trial, which showed that siltuximab led to a reduced mortality rate from COVID-19.
Research has shown oral hormone therapy significantly impacts the metabolome of postmenopausal women, explaining certain disease risks.